Focus: B. Braun is a German-headquartered specialty pharmaceutical and medical device company focused on infusion therapy, pain management, and clinical nutrition. The company operates across cardiovascular, infectious disease, metabolic, nephrology, and neurology therapeutic areas with a mature, established market presence.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow B. Braun to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from B. Braun's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core revenue driver but generic standard-of-care with no differentiation and approaching exclusivity cliff.
Help build intelligence for B. Braun
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Combination infusion therapy for multi-electrolyte management facing LOE with limited clinical differentiation.
Standard IV solution combination nearing patent expiry with generic competition inevitable.
Branded IV combination approaching LOE in a commoditized infusion therapy space.
Niche electrolyte solution with approaching LOE and minimal differentiation.
Specialized parenteral nutrition formulation for renal patients with sustained but niche market demand.
Low-sodium IV combination formula nearing LOE in a competitive, price-sensitive segment.
Cardiac-indicated IV solution with approaching LOE and generic market pressure.
Pre-filled heparin IV solution facing LOE as heparin is off-patent and subject to intense generic competition.
Dilute electrolyte IV solution nearing LOE in a saturated, low-margin market.
143 discontinued, 91 duplicate formulations not shown
+32 more products
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
Active drug shortage status on two products (Lidocaine Hydrochloride Injection, Dextrose 10% Injection) suggests supply chain vulnerabilities or manufacturing constraints that may impact operational stability and employee workload.
+2 more